Vesnarinone prolongs action potential duration without reverse frequency dependence in rabbit ventricular muscle by blocking the delayed rectifier K+ current

Circulation

Volumn 96, Issue 10, 1997, Pages 3696-3703

  Toyama, Junji ^b   Kamiya, Kaichiro ^a   Cheng, Jianhua ^b   Lee, Jong Kook ^b   Suzuki, Ryoko ^b   Kodama, Itsuo ^b  

^a NAGOYA UNIVERSITY   (Japan)

^b NONE

Author keywords

Action potentials; Arrhythmia; Potassium channels

Indexed keywords

PIPERANOMETOZINE;

ACTION POTENTIAL; ARTICLE; HEART ARRHYTHMIA; HEART PAPILLARY MUSCLE; HEART VENTRICLE; HEART VENTRICLE CONTRACTILITY; HYPERPOLARIZATION; MUSCLE CONTRACTILITY; POTASSIUM CURRENT; PRIORITY JOURNAL; RABBIT; SINUS NODE;

EID: 0030732121     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.10.3696     Document Type: Article

References (59)

1. Sasayama S, Inoue M, Asanoi H, Kodama K, Hori M, Sakurai T, Kawai C. Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure. Heart Vessels. 1986; 2:23-28.
2. Sasayama S. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. Cardiovasc Drugs Ther. 1990;4:419-426.
3. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG, for the Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med. 1993;329:149-155.
4. Iijima T, Taira N. Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart. J Pharmacol Exp Ther. 1987;240:657-662.
5. 2+ channels in ventricular myocytes of guinea pig. J Cardiovasc Pharmacol. 1989;13:812-819.
6. Lathrop DA, Nanasi PP, Schwartz A, Varro A. Ionic basis for OPC-8212-induced increase in action potential duration in isolated rabbit guinea pig and human ventricular myocytes. Eur J Pharmacol. 1993;240:127-137.
7. Matsui S, Matsumori A, Matoba Y, Uchida A, Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone: suppression of natural killer cell activity and tumor necrosis factor-alpha production. J Clin Invest. 1994;94:1212-1217.
8. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 1994;89:955-958.
9. Shioi T, Matsumori A, Matsui S, Sasayama S. Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line. Life Sci. 1994;54: 11-16.
10. Yamada T, Matsumori A, Sasayama S. Therapeutic effect of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation. 1994;89:846-851.
11. Asanoi H, Sasayama S, Kameyama T, Ishizaka S, Iuchi K. Sustained inotropic effects of a new cardiotonic agent, OPC-8212 in patients with chronic heart failure. Clin Cardiol. 1989;12:133-138.
12. + current in sinoatrial node pacemaker activity. Am J Physiol. 1995; 269:H453-H462.
13. Carlsson L, Abrahamsson C, Almgren O, Lundberg C, Duker G. Prolonged action potential duration and positive inotropy induced by the novel class III antiarrhythmic agent H 234/09 (almokalant) in isolated human ventricular muscle. J Cardiovasc Pharmacol. 1991; 18:882-887.
14. Wallace AA, Stupienski R3, Brookes LM, Selnick HG, Claremon DA, Lynch JJ. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs. J Cardiovasc Pharmacol. 1991;18: 687-695.
15. Abrahamsson C, Duker G, Lundberg C, Carlsson L. Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031. Cardiovasc Res. 1993;27:861-867.
16. Schmitt C, Brachmann J, Karch M, Waldecker B, Navarrete L, Montero M, Beyer T, Kubler W. Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potentials of the right ventricle. Am J Cardiol. 1991;68:1183-1187.
17. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther. 1992;262:809-817.
18. + current by almokalant in rabbit ventricular myocytes. Circ Res. 1993;73:857-868.
19. + current in rabbit ventricular myocytes. Cardiovasc Drugs Ther. 1993;3: 599-604.
20. + current by dofetilide. Circ Res. 1993;72:75-83.
21. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use dependence. Circulation. 1990;81:686-690.
22. Singh BN. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact. Eur Heart J. 1993; 14(suppl H):14-23.
23. Okada Y, Ogawa S, Sadanaga T, Mitamura H. Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography. J Am Coll Cardiol. 1996;27:84-89.
24. 2+-calmodulin mediated modulation of the electrical coupling of ventricular myocytes isolated from guinea pig heart. J Mol Cell Cardiol. 1994;26:1007-1015.
25. Hamil OP, Marty A, Neher E, Sakmann B, Sigworth F. Improved patch-clamp techniques for high resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981;391: 85-100.
26. + current in rabbit ventricular myocytes. Cardiovasc Res. 1996;31: 963-974.
27. Kodama I, Suzuki R, Kamiya K, Iwata H, Toyama J. Effects of long-term oral administration of amiodarone on the electromechanical performance of rabbit ventricular muscle. Br J Pharmacol. 1992;107:502-509.
28. Kr, and effects on myocardial refractoriness for class III antiarrhythmic agents. J Cardiovasc Pharmacol. 1995; 25:336-340.
29. + current: differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol. 1990;96:195-215.
30. Veldkamp MW, van Ginneken ACG, Bouman LN. Single delayed rectifier channels in the membrane of rabbit ventricular myocytes. Circ Res. 1993;72:865-878.
31. Ohler A, Ravens U. Effects of E-4031, almokalant and tedisamil on postrest action potential duration of human papillary muscles. J Pharmacol Exp Ther. 1994;270:460-465.
32. Ks. Am J Physiol. 1996;271:H2477-H2489.
33. + current in human ventricular myocytes. Circ Res. 1996;78:689-696.
34. Yue L, Feng J, Li GR, Nattel S. Transient outward and delayed rectifier currents in canine atrium: properties and role of isolation methods. Am J Physiol. 1996;H2157-H2168.
35. Iwata H, Kodama I, Suzuki R, Kamiya K, Toyama J. Effects of long-term oral administration of amiodarone on the ventricular repolarization of rabbit hearts. Jpn Circ J. 1996;60:662-672.
36. Zhang ZH, Follmer CH, Sarma JSM, Chen F, Singh BN. Effect of ambasilide, a new class III agent, on plateau currents in isolated guinea pig ventricular myocytes: block of delayed outward potassium current. J Pharmacol Exp Ther. 1992;263:40-48.
37. c antiarrhythmic drugs: evidence for open channel block and unblock. Cardiovasc Res. 1992;26:1121-1130.
38. Nademanee K, Stevenson WG, Weiss JN, Frame VB, Antimisiaris MG, Suithichaiyakul T, Pruitt CM. Frequency-dependent effects of quinidine on the ventricular action potential and QRS duration in humans. Circulation. 1990;81:790-796.
39. Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Circ Res. 1985;56:857-867.
40. Sadanaga T, Ogawa S, Okada Y, Tsutsumi N, Iwanaga S, Yoshikawa T, Akaishi M, Handa S. Clinical evaluation of the use-dependent QRS prolongation and the reverse use-dependent QT prolongation of class I and class III antiarrhythmic agents and their value in predicting efficacy. Am Heart J. 1993;126:114-121.
41. Kr) in AT-1 cells. concentration-, time-, voltage-, and use-dependent effects. Circulation. 1995;91: 1799-1806.
42. Snyders DJ, Knoth KM, Roberds SL, Tamkun MM. Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. Mol Pharmacol. 1992;41:322-330.
43. Snyders DJ, Chaudhary A. High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol. 1996;49:949-955.
44. + channel. Circ Res. 1993;72:707-714.
45. Kr potassium channel. Cell. 1995;81:299-307.
46. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, Keating MT. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature. 1996;384: 80-83.
47. Ks contributes to the longer action potential of the M cell. Circ Res. 1995;76:351-365.
48. Sanguinetti MC, Jurkiewicz NK, Scott A, Siegi PK. Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes: mechanism of action. Circ Res. 1991;68:77-84.
49. Toyama J, Kamiya K, Cheng J, Lee JK, Suzuki R, Kodama I. Ion channel blockers in the treatment of chronic heart failure. J Cardiovasc Failure. 1996;2:S243-S249.
50. Lathrop DA, Varro A, Schwartz A. Rate-dependent electrophysiological effects of OPC-8212: comparison to sotalol. Eur J Pharmacol. 1989;164:487-496.
51. DiFrancesco D, Noble D. A model of cardiac electrical activity incorporating ionic pumps and concentration changes. Phil Trans R Soc Lond. 1985;B307:353-398.
52. Beeler GW, Reuter H. Reconstruction of the action potential of ventricular myocardial fibers. J Physiol. 1977;268:177-210.
53. Hilgemann DW, Noble D. Excitation-contraction coupling and extracellular calcium transients in rabbit atrium: reconstruction of basic cellular mechanisms. Proc R Soc Lond. 1987;B230:163-205.
54. Egan TM, Noble D, Noble SJ, Powell T, Twist VW, Yamaoka K. On, the mechanism of isoprenaline- and forskolin-induced depolarization of single guinea-pig ventricular myocytes. J Physiol. 1988; 400:299-320.
55. Carmeliet E. Action potential duration and refractoriness. In: Sigh BN, Wellens HJJ, Hiraoka M, ed. Electropharmacological Control of Cardiac Arrhythmias: To Delay Conduction or to Prolong Refractoriness? Mount Kisco, NY: Futura; 1994:33-46.
56. c, and class III drugs on reentrant ventricular tachycardia: importance of the excitable gap for the inducibility of double-wave reentry. Circulation. 1994;90:1012-1022.
57. Inoue H, Yamashita T, Nozaki A, Sugimoto T. Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap. J Am Coll Cardiol. 1991;18:1098-1104.
58. Fei L, Slade AK, Grace AA, Malik M, Camm AJ, McKenna WJ. Ambulatory assessment of the QT interval in patients with hypertrophic cardiomyopathy: risk stratification and effect of low dose amiodarone. Pacing Clin Electrophysiol. 1994;17: 2222-2227.
59. Sager PT, Uppal P, Follmer C, Antimisiaris M, Pruitt C, Singh BN. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation. 1993;88:1063-1071.